Neurological manifestations of antiphospholipid syndrome

European Journal of Clinical Investigation

Volumn 40, Issue 4, 2010, Pages 350-359

  Rodrigues, Carlos E M ^a   Carvalho, Jozélio F ^a   Shoenfeld, Yehuda ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Neurological manifestations

Indexed keywords

ACETYLSALICYLIC ACID; CARDIOLIPIN ANTIBODY; CLOPIDOGREL; HEPARIN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PHOSPHOLIPID ANTIBODY; PREDNISONE; RITUXIMAB; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHOREA; CLINICAL FEATURE; COGNITIVE DEFECT; CONVULSION; DEMENTIA; DISEASE ASSOCIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROPHYSIOLOGY; EPILEPSY; EYE DISEASE; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MIGRAINE; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; MYELITIS; NERVOUS TISSUE; NEUROLOGIC DISEASE; PATHOGENESIS; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SNEDDON SYNDROME; SPINAL CORD DISEASE; STROKE; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; HUMANS; NERVOUS SYSTEM DISEASES;

EID: 77949707015     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02263.x     Document Type: Review

References (97)

1. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000 15 : 145 152.
2. Cervera R, Boffa M-C, Khamastha MA, Hughes GRU. The Euro-Phospholipid Project epidemiology of the antiphospholipid syndrome in Europe. Lupus 2009 18 (Spec No 889 893.
3. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002 346 : 752 763.
4. Hughes GRV. Thrombosis, abortion, cerebral disease and the lupus anticoagulant. BMJ 1983 287 : 1088 1089.
5. Harris EN, Englert H, Derue G. Antiphospholipid antibodies in acute Guillain-Barre syndrome. Lancet 1983 ii : 1361 1362.
6. Hughes GRV. The Prosser-White oration 1983. Connective tissue disease and the skin. Clin Exp Dermatol 1984 9 : 535 544.
7. Harris EN, Gharavi AE, Mackworth-Young CG, Patel BM, Derue G, Hughes GR. Lupoid sclerosis: a possible pathogenetic role for antiphospholipid antibodies. Ann Rheum Dis 1985 44 : 281 283.
8. Asherson RA, Mercey D, Phillips G, Sheehan N, Gharavi AE, Harris EN et al. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis 1987 46 : 605 611.
9. Sanna G, DÇruz D, Cuadrado MJ. Cerebral manifestations in the antiphospholipid (Hughes) syndrome. Rheum Dis Clin North Am 2006 32 : 465 490.
10. Cuadrado MJ, Khamashta MA, Ballesteros A, Godfrey T, Simon MJ, Hughes GR. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature Medicine (Baltimore) 2000 79 : 57 68.
11. Cuadrado MJ, Khamashta MA, D'Cruz DL. Migraine in Hughes syndrome. Heparin as a therapeutic trial?. Q J Med 2001 94 : 114 115.
12. Hughes GR. Migraine, memory loss, and ''multiple sclerosis.'' Neurological features of the antiphospholipid (Hughes') syndrome. Postgrad Med J 2003 79 : 81 3.
13. Shoenfeld Y, Lev S, Blatt I, Blank M, Font J, vonLandenberg P et al. Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol 2004 31 : 1344 1348.
14. Gomez-Puerta JA, Cervera R, Calvo LM, GomezAnson B, Espinosa G, Claver G et al. Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients. Rheumatology (Oxford) 2005 44 : 95 9.
15. Rodrigues CEM, Carvalho JF. Multiple mononeuropathy secondary to thrombosis of the vasa nervorum in primary antiphospholipid syndrome: the first reported case. Isr Med Assoc J 2009 (in press).
16. Tanne D, Hassin-Baer S. Neurologic manifestation of the antiphospholipid syndrome. Curr Rheumatol Rep 2001 3 : 286 292.
17. Hoppensteadt DA, Fabbrini N, Bick RL, Messmore HL, Adiguzel C, Fareed J. Laboratory evaluation of the antiphospholipid syndrome. Hematol Oncol Clin North Am 2008 22 : 19 32.
18. Oosting JD, Derksen RH, Blokzijl L, Sixma JJ, de Groot PG. Antiphospholipid antibody positive sera enhance endothelial cell procoagulant activity - studies in a thrombosis model. Thromb Haemost 1992 68 : 278 284.
19. Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995 96 : 2211 2219.
20. Del Papa N, Guidali L, Sala A, Buccellati C, Khamashta MA, Ichikawa K et al. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum 1997 40 : 551 561.
21. Meroni PL, Tincani A, Sepp N, Raschi E, Testoni C, Corsini E et al. Endothelium and the brain in CNS lupus. Lupus 2003 12 : 919 928.
22. Connor P, Hunt BJ. Cerebral haemostasis and antiphospholipid antibodies. Lupus 2003 12 : 929 934.
23. Sun KH, Liu WT, Tsai CY, Liao TS, Lin WM, Yu CL. Inhibition of astrocyte proliferation and binding to brain tissue of anticardiolipin antibodies purified from lupus serum. Ann Rheum Dis 1992 51 : 707 712.
24. Khalili A, Cooper RC. A study of immune responses to myelin and cardiolipin in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1991 85 : 365 372.
25. Katzav A, Chapman J, Shoenfeld Y. CNS dysfunction in the antiphospholipid syndrome. Lupus 2003 12 : 903 907.
26. Liou HH, Wang CR, Chou HC, Arvanov VL, Chen RC, Chang YC et al. Anticardiolipin antisera from lupus patients with seizures reduce a GABA receptor-mediated chloride current in snail neurons. Life Sci 1994 54 : 1119 1125.
27. Shoenfeld Y, Nahum A, Korczyn AD, Dano M, Rabinowitz R, Beilin O et al. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 2003 12 : 436 442.
28. Hanly JG. Antiphospholipid syndrome: an overview. CMAJ 2003 168 : 1675 1682.
29. George J, Harats D, Gilburd B, Arnon A, Yair L, Jacob S et al. Immunolocalization of beta2-glycoprotein I(apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 1999 99 : 2227 2230.
30. Hilker R, Thiel A, Geisen C, Rudolfl J. Cerebral blood flow and glucose metabolism in multi-infarct-dementia related to primary antiphospholipid antibody syndrome. Lupus 2000 9 : 311 316.
31. Terashi H, Uchiyama S, Hashimoto S, Miyazaki K, Tsutsumi Y, Yamazaki M et al. Clinical characteristics of stroke patients with antiphospholipid antibodies. Cerebrovasc Dis 2005 19 : 384 390.
32. Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RH, Machin SJ, Barquinero J et al. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989 68 : 366 374.
33. Bick R, Baker W. Antiphospholipid syndrome and thrombosis. Semin Thromb Hemost 1999 25 : 333 350.
34. Asherson RA, Khamashta MA, Gil A, Vazquez JJ, Chan O, Baguley E et al. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. Am J Med 1989 86 : 391 399.
35. Gezer S. Antiphospholipid syndrome. Dis Mon 2003 49 : 696 741.
36. Group APASS. Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. Neurology 1997 48 : 91 4.
37. Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciacca RR et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004 291 : 576 584.
38. Janardhan V, Wolf PA, Kase CS, Massaro JM, D'Agostino RB, Franzblau C et al. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. Stroke 2004 35 : 736 741.
39. Brey RL, Stallworth CL, McGlasson DL, Wozniak MA, Wityk RJ, Stern BJ et al. Antiphospholipid antibodies and stroke in young women. Stroke 2002 33 : 2396 2400.
40. Avcin T, Cimaz R, Rozman B, Ped-APS Registry Collaborative Group. The Ped-APS Registry: the antiphospholipid syndrome in childhood. Lupus 2009 18 : 894 899.
41. Hunt BJ. Pediatric antiphospholipid antibodies and antiphospholipid syndrome. Semin Thromb Hemost 2008 34 : 274 281.
42. Rigante D, Gaspari S, Bersani G, Stabile A. Anti-phospholipid syndrome: clinical spectrum and therapeutical/prophylactic strategies in the pediatric population. Eur Rev Med Pharmacol Sci 2008 126 : 47 53.
43. Kenet G, Sadetzki S, Murad H, Martinowitz U, Rosenberg N, Gitel S et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 2000 31 : 1283 1288.
44. Levine SR, Langer SL, Albers JW, Welch KM. Sneddon's syndrome: an antiphospholipid antibody syndrome? Neurology 1988 38 : 798 800.
45. Alegre VA, Winkelmann RK, Gastineau DA. Cutaneous thrombosis, cerebrovascular thrombosis, and lupus anticoagulant - the Sneddon syndrome. Report of 10 cases. Int J Dermatol 1990 29 : 45 9.
46. Sinharay R. Sneddon's syndrome: additional neurological feature in antiphospholipid (Hughes') syndrome. Postgrad Med J 2003 79 : 550.
47. Asherson RA, Cervera R. Unusual manifestations of the antiphospholipid syndrome. Clin Rev Allergy Immunol 2003 25 : 61 78.
48. Frances C, Papo T, Wechsler B, Laporte JL, Biousse V, Piette JC. Sneddon syndrome with or without antiphospholipid antibodies: a comparative study in 46 patients. Medicine 1999 78 : 209 219.
49. Fetoni V, Grisoli M, Salmaggi A. Clinical and neuroradiological aspects of Sneddon's syndrome and primary antiphospholipid antibody syndrome: a follow-up study. Neurol Sci 2000 21 : 157 164.
50. Kim JH, Lee SI, Park SI, Yoo WH. Recurrent transverse myelitis in primary antiphospholipid syndrome - case report and literature review. Rheumatol Int 2004 24 : 244 246.
51. D'Cruz DP, Mellor-Pita S, Joven B, Sanna G, Allanson J, Taylor J et al. Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol 2004 31 : 280 285.
52. Mok CC, Lau CS, Chan EY, Wong RW. Acute transverse myelitis in systemic lupus erythematosus: clinical presentation, treatment, and outcome. J Rheumatol 1998 25 : 467 473.
53. Lavelle C, Pizarro S, Drenkard C, Sanchez-Guerrero J, Alarcon-Segovia D. Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. J Rheumatol 1990 17 : 34 7.
54. Cimaz R, Meroni PL, Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus 2006 15 : 191 197.
55. Cocito L, Favale E, Reni L. Epileptic seizures in cerebral arterial occlusive disease. Stroke 1982 13 : 189 195.
56. Herranz MT, Rivier G, Khamashta MA, Blaser KU, Hughes GR. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum 1994 37 : 568 571.
57. Xie XK, Tang LO. Observation on anti-brain antibody in serum of 110 epileptics. Chin Med J 1990 103 : 71 5.
58. Kwan P, Sills GJ, Kelly K, Butler E, Brodie MJ. Glutamic acid decarboxylase autoantibodies in controlled and uncontrolled epilepsy: a pilot study. Epilepsy Res 2000 42 : 191 195.
59. Peltola J, Kulmala P, Isojarvi J, Saiz A, Latvala K, Palmio J et al. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology 2000 55 : 46 50.
60. Takahashi Y, Mori H, Mishina M, Watanabe M, Kondo N, Shimomura J et al. Autoantibodies and cell-mediated autoimmunity to NMDA-type GluRepsilon2 in patients with Rasmussen's encephalitis and chronic progressive epilepsia partialis continua. Epilepsia 2005 46 : 152 158.
61. Ranua J, Luoma K, Auvinen A, Haapala AM, Mäki M, Peltola J et al. Antimitochondrial antibodies in patients with epilepsy. Epilepsy Behav 2005 7 : 95 7.
62. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002 46 : 1019 1027.
63. Miesbach W, Gilzinger A, Gokpinar B, Claus D, Scharrer I. Prevalence of antiphospholipid antibodies in patients with neurological symptoms. Clin Neurol Neurosurg 2006 108 : 135 142.
64. Sanna G, Bertolaccini ML, Cuadrado MJ. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology (Oxford) 2003 42 : 200 213.
65. Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999 8 : 127 133.
66. Angelini L, Zibordi F, Zorzi G, Nardocci N, Caporali R, Ravelli A et al. Neurological disorders, other than stroke, associated with antiphospholipid antibodies in childhood. Neuropediatrics 1996 27 : 149 153.
67. Nardocci N, Zorzi G, Grisoli M, Rumi V, Broggi G, Angelini L. Acquired hemidystonia in childhood: a clinical and neuroradiological study of thirteen patients. Pediatr Neurol 1996 15 : 108 113.
68. Milanov I, Bogdanova D. Antiphospholipid syndrome and dystonia-parkinsonism. A case report. Parkinsonism Relat Disord 2001 7 : 139 141.
69. Cuadrado MJ, Sanna G. Headache and systemic lupus erythematosus. Lupus 2003 12 : 943 946.
70. Montalban J, Cervera R, Font J, Ordi J, Vianna J, Haga HJ et al. Lack of association between anticardiolipin antibodies and migraine in systemic lupus erythematosus. Neurology 1992 42 : 681 682.
71. Tietjen GE, Day M, Norris L, Aurora S, Halvorsen A, Schultz LR et al. Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events: a prospective study. Neurology 1998 50 : 1433 1440.
72. Levine SR, Joseph R, D'Andrea G, Welch KM. Migraine and the lupus anticoagulant. Case reports and review of the literature. Cephalalgia 1987 7 : 93 9.
73. Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L, Cabiedes J et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989 68 : 353 365.
74. Verrotti A, Cieri F, Pelliccia P, Morgese G, Chiarelli F. Lack of association between antiphospholipid antibodies and migraine in children. Int J Clin Lab Res 2000 30 : 109 111.
75. Arnson Y, Shoenfeld Y, Alon E, Amital H. The antiphospholipid syndrome as a neurological disease. Semin Arthritis Rheum (in press).
76. Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003 30 : 985 992.
77. Pras E, Neumann R, Zandman-Goddard G, Assia EI, Shoenfeld Y et al. Intraocular inflammation in autoimmune diseases. Semin Arthritis Rheum 2004 34 : 602 609.
78. Suvajac G, Stojanovich L, Milenkovich S. Ocular manifestations in antiphospholipid syndrome. Autoimmun Rev 2007 6 : 409 414.
79. Miserocchi E, Baltatzis S, Foster S. Ocular features associated with antibodies: a descriptive study. Am J Ophtalmol 2001 131 : 451 456.
80. Tourbah A, Clapin A, Gout O, Fontaine B, Liblau R, Batteux F et al. Systemic autoimmune features and multiple sclerosis: a 5-year follow-up study. Arch Neurol 1998 55 : 517 521.
81. Sastre-Garriga J, Reverter JC, Font J, Tintoré M, Espinosa G, Montalban X. Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis. Ann Neurol 2001 49 : 408 411.
82. Heinzlef O, Weill B, Johanet C, Sazdovitch V, Caillat-Zucman S, Tournier-Lasserve E et al. Anticardiolipin antibodies in patients with multiple sclerosis do not represent a subgroup of patients according to clinical, familial, and biological characteristics. J Neurol Neurosurg Psychiatry 2002 72 : 647 649.
83. Paran D, Chapman J, Korczyn AD, Elkayam O, Hilkevich O, Groozman GB et al. Evoked potential studies in the antiphospholipid syndrome: differential diagnosis from multiple sclerosis. Ann Rheum Dis 2006 65 : 525 528.
84. Roldan JF, Brey RL. Neurologic Manifestations of the Antiphospholipid Syndrome. Curr Rheumatol Rep 2007 9 : 109 115.
85. Erkinjuntti T, Bowler JV, DeCarli CS. Imaging of static brain lesions in vascular dementia: implications for clinical trials. Alzheimer Dis Assoc Disord 1999 13 : 81 90.
86. Gilburd B, Stein M, Tomer Y, Tanne D, Abramski O, Chapman Y et al. Autoantibodies to phospholipids and brain extract in patients with the Guillain-Barre syndrome: cross-reactive or pathogenic? Autoimmunity 1993 16 : 23 7.
87. Erten N, Saka B, Karan MA, Parman Y, Umman B, Tascioglu C. Catastrophic secondary antiphospholipid syndrome with peripheral nervous system involvement: a case report. Acta Med Okayama 2004 58 : 107 110.
88. Miiesbah W. Neurologic symptoms as a feature of the antiphospholipid syndrome. Semin Thromb Haemost 2008 34 : 286 289.
89. McCombe PA, McLeod JG, Pollard JD, Guo YP, Ingall TJ. Peripheral sensorimotor and autonomic neuropathy associated with systemic lupus erythematosus. Clinical, pathological and immunological features. Brain 1987 110 : 533 534.
90. Jeruc J, Popovic M, Vizjak A, Jurcic V, Lestan B, Ferluga D. Multiple mononeuropathy due to vasculitis associated with anticardiolipin antibodies: a case report. Folia Neuropathol 2006 44 : 140 143.
91. Lackner JK, Peetz D, Landenberg P. Revision of the Sapporo criteria for the antiphospholipid syndrome - coming to grips with evidence and Thomas Bayes? Thromb Haemost 2006 95 : 917 919.
92. Santos MSF, Carvalho JF, Brotto M, Bonfa E, Rocha FA. Peripheral neuropathy in patients with primary antiphospholipid (Hughes') syndrome. Lupus (in press).
93. Hughes GRV. Hughes syndrome (the antiphospholipid syndrome) ten clinical lessons. Autoimmun Rev 2008 7 : 262 266.
94. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 1995 332 : 993 997.
95. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003 349 : 1133 1138.
96. Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992 117 : 303 308.
97. Blank M, Anafi L, Zandman-Goddard G, Krause I, Goldman S, Shalev E et al. The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol 2007 19 : 857 865.